Lungentuberkulose unter Therapie mit Tocilizumab/Etanercept

Zusammenfassung

In unserer Ambulanz wurde bei einer 82-jährigen Patientin nach Diagnose einer late onset seropositiven ACPA-negativen Rheumatoiden Arthritis (LORA) zunächst eine Therapie mit Leflunomid begonnen. Im Verlauf musste die Therapie auf Etanercept gewechselt werden. Bei positivem Quantiferontest erfolgte eine Chemoprävention mit Rifampicin. Im Verlauf präsentierte sich die Patientin mit der Diagnose einer Großgefäßvaskulitis, in der Rückschau lag also initial eine Polymyalgia rheumatica (PMR) vor. Die Therapie wurde auf Tocilizumab geändert und die Pat. erhielt einen Prednisolonstoß. Unter der Therapie mit Tocilizumab/Prednisolon entwickelte die Patientin eine polysensible Lungentuberkulose.

Abstract

In our outpatient clinic, an 82-year-old female patient was diagnosed with late-onset seropositive ACPA-negative rheumatoid arthritis (LORA) and was started on treatment with leflunomide. In the course of that treatment, the medication had to be changed to etanercept. The QuantiFERON test showed a positive result and chemoprevention with rifampicin was started. During that treatment, the patient presented with a diagnosis of large-vessel vasculitis, which means that, in retrospect, the initial condition had been polymyalgia rheumatica (PMR). The medication was changed to tocilizumab and the patient received a prednisolone shot. During the treatment with tocilizumab/prednisolone, the patient developed poly-sensitive pulmonary tuberculosis.

Schlüsselwörter

Tuberkulose - Tocilizumab - Etanercept

Key words

Tuberculosis - Tocilizumab - Etanercept

Publikationsverlauf

Artikel online veröffentlicht:
04. Oktober 2023

• Literatur

• 1 Ceccato F, Roverano SG, Papasidero S. et al. Peripheral musculoskeletal manifestations in polymyalgia rheumatica. J Clin Rheumatol 2006; 12: 167-171 PMID: 16891918
• 2 Dasgupta B, Cimmino MA, Maradit-Kremers H. et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Annals of the Rheumatic Diseases 2012; 71: 484-492
• 3 Fragoulis GE, Nikiphorou E, Dey M. et al. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Annals of the Rheumatic Diseases Published Online First 2022;
• 4 Schaberg T. et al S2k-Leitlinie: Tuberkulose im Erwachsenenalter. Pneumologie 2017; 71: 325-397 Update 2022
• 5 Diel R. et al. Joint Statement on the Tuberculosis Risk with Treament Using Noval Non-TNF Alpha Biologicals. Pneumologie 2021; 75: 293-303
• 6 McAllister WA, Thompson PJ, Al-Habet SM. et al. Rifampicin reduces effectiveness and bioavailability of prednisolone. Br Med J (Clin Res Ed) 1983; 286: 923-925
• 7 Askling J, Fored CM, Brandt L. et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005; 52: 1986-1992
• 8 Seong SS, Choi CB, Woo JH. et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007; 34: 706-711
• 9 Tubach F, Salmon D, Ravaud P. et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum 2009; 60: 1884-1894
• 10 Evangelatos G, Koulouri V, Iliopoulos A. et al. Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors. Ther Adv Musculoskelet Dis 2020; 12: 1759720X20930116
• 11 Jung SM, Han M, Kim EH. et al. Comparison of developing tuberculosis following tumor necrosis factor inhibition and interleukin-6 inhibition in patients with rheumatoid arthritis: a nationwide observational study in South Korea, 2013–2018. Arthritis Res Ther 2022; 24: 157 PMID: 35761359; PMCID: PMC9235163.
• 12 Mack U, Migliori GB, Sester M. et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009; 33: 956-973
• 13 Menzies D, Adjobimey M, Ruslami R. et al. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. N Engl J Med 2018; 379: 440-453
• 14 World Health Organization. WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment. Geneva: World Health Organization; 2020